You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

nonsquamous non-small-cell lung cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Non Small Cell Lung Cancer, Brain Metastases Trial (Cadonilimab)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Brain Metastases
  • (no location specified)
Apr 2, 2023

Lung Cancer, Non-squamous, Non-small Cell Trial (zongertinib, pembrolizumab, cisplatin)

Not yet recruiting
  • Lung Cancer, Non-squamous, Non-small Cell
  • (no location specified)
Nov 22, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

Metastatic NSCLC, Stage III NSCLC Trial (inupadenant, Placebo, Carboplatin)

Recruiting
  • Metastatic NSCLC
  • Stage III NSCLC
  • Fayetteville, Arkansas
  • +16 more
Jan 25, 2023

Non-Small-Cell Lung Carcinoma Trial (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • (no location specified)
Aug 16, 2022

Non Small Cell Lung Cancer Trial in Cleveland (Liquid biopsy)

Recruiting
  • Non Small Cell Lung Cancer
  • Liquid biopsy
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 6, 2022

Nonsquamous NSCLC Trial in Yichang (Sintilimab, Docetaxel, Pemetrexed)

Recruiting
  • Nonsquamous Non-Small Cell Lung Cancer
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021

Nonsquamous NSCLC Trial in Yichang (Sintilimab, Docetaxel, Pemetrexed)

Recruiting
  • Nonsquamous Non-Small Cell Lung Cancer
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021

Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Seattle

Not yet recruiting
  • Lung Non-Squamous Non-Small Cell Carcinoma
  • +3 more
  • CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
  • Sargramostim
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 11, 2022

Non-Small-Cell Lung Carcinoma Trial in Japan (biological, drug, dietary supplement)

Active, not recruiting
Has Results
  • Non-Small-Cell Lung Carcinoma
  • Pembrolizumab 200 mg
  • +7 more
  • Nagoya, Aichi, Japan
  • +9 more
Jan 23, 2023

NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Jun 26, 2023

Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

Not yet recruiting
  • Advanced Non-squamous Non-small-cell Lung Cancer
  • +2 more
  • Beijing, Beijing, China
    Peking University First Hospital Ethics Committee
Sep 10, 2023

Nonsquamous NSCLC Trial in China (Pembrolizumab, Carboplatin, Cisplatin)

Active, not recruiting
  • Nonsquamous Non-small Cell Lung Cancer
  • Pembrolizumab
  • +5 more
  • Beijing, Beijing, China
  • +18 more
Dec 2, 2021

Nonsquamous Nonsmall Cell Tumor of Lung Trial in Taipei (BLEX 404)

Not yet recruiting
  • Nonsquamous Nonsmall Cell Neoplasm of Lung
  • BLEX 404
  • Taipei, Taiwan
    Taipei Veteran General Hospital
Feb 28, 2023

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line

Completed
  • Non-squamous NSCLC
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Nonsquamous NSCLC Trial in China (HX008, Pembrolizumab, pemetrexed)

    Recruiting
    • Nonsquamous Non-small Cell Lung Cancer
    • Hefei, Anhui, China
    • +9 more
    Feb 7, 2021

    NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • NSCLC, Stage III
    • Beijing, Beijing, China
      Beijing Tsinghua Chang Gung Hospital
    Nov 4, 2022

    Non Small Cell Lung Cancer Trial in Wuhan (Carrelizumab, Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC),

    Recruiting
    • Non Small Cell Lung Cancer
    • Wuhan, China
      Wuhan Union Hospital
    Aug 27, 2021

    Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer Trial in Worldwide

    Recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • Dhaka, Bangladesh
    • +139 more
    Dec 8, 2022

    Non Small Cell Lung Cancer Trial in Worldwide (Pemetrexed, Cisplatin, Necitumumab)

    Completed
    Has Results
    • Non Small Cell Lung Cancer
    • Nyack, New York
    • +100 more
    Dec 12, 2021

    Double-dose Furmonertinib in Treatment of Slow

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Oct 31, 2023

    Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)

    Recruiting
    • Advanced Non-squamous Non-Small-Cell Lung Cancer
    • Jinan, Shandong, China
      The First Affiliated Hospital of Shandong First Medical Universi
    Dec 4, 2022

    NSCLC Trial in Tampa, Philadelphia (Durvalumab, Carboplatin, Abequolixron)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Tampa, Florida
    • +1 more
    Jun 9, 2023

    NSCLC Trial in Shanghai

    Not yet recruiting
    • Non-small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Pulmonary Hospital
      Jul 20, 2023